



EXHIBITION AND FLOOR PLAN

GROUND FLOOR



FIRST FLOOR



TIME	SUNDAY JUNE 19
11.30-14.00	Registration
14.00-14.15	Opening Anders Karlén, Jeff Zablocki, Gerhard Ecker
14.15-15.00	Activity-based proteomics – applications for enzyme and inhibitor discovery Ben Cravatt, The Scripps Research Institute, USA
15.00-15.45	Translating medicinal chemistry research into targeted therapeutics. building on academic knowledge. Roberto Pellicciari, University of Perugia, Italy
15.45-17.00	POSTER SESSION I with coffee
SESSION 1 GPCR's Chair: Jeff Zablocki	
17.00-17.30	Development of allosteric modulators of GPCRs for CNS disorders Bruce Melancon, Vanderbilt University, USA
17.30-18.00	Development of first in class peripherally restricted CB1 receptor antagonists for treatment of obesity and type 2 diabetes Thomas Högberg, LEO Pharma, Denmark
19.15	Reception at the City Hall

TIME MONDAY JUNE 20	
SESSION 2 Case studies and emerging targets Chair: Åsa Rosenquist	
09.00-09.30	Nuclear hormone receptors – ligand design, predictions and reality Thomas Olsson, AstraZeneca, Sweden
09.30-10.00	Design of cathepsin K inhibitors, displaying whole blood stability, for the treatment of osteoporosis, osteoarthritis and other bone-related diseases Urszula Gabrowska, Medivir, Sweden
10.00-10.30	Chemokine antagonists in the combat of inflammatory diseases Rolf Johansson, AstraZeneca, Sweden
10.30-11.00 Coffee and Exhibition	
SESSION 3 Chemical neuroscience and selected short talks Chair: Bob Devita	
11.00-11.30	Discovery of cyclic acylguanidines as orally active BACE inhibitors Andy Stamford, Merck Research Laboratories, USA
11.30-12.00	Approaches to the treatment of schizophrenia Klaus Bæk Simonsen, Lundbeck, Denmark
Short talks Chair: Rasmus Prætorius Clausen	
12.15-12.25	Optimization and characterization of functionally selective agonists of the m1 acetylcholine receptor James Tarr, Vanderbilt University, USA
12.25-12.35	Irreversible ligands for the first crystallization of an agonist-bound beta2 adrenoceptor Ralph Holl, Westfälische Wilhelms-Universität Münster, Germany
12.35-12.45	Pilicides & curlicides – antibacterial agents targeting bacterial virulence Fredrik Almqvist, Umeå University, Sweden
12.45-13.45 Lunch and Exhibition	
13.45-15.15 POSTER SESSION II	
SESSION 4 Emerging topics Chair: Christian Krog-Jensen	
15.15-15.45	Application of PET and SPECT radiotracers in drug development Gilles Tamagnan, Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA
15.45-16.15	The Human Protein Atlas Mathias Uhlén, Royal Institute of Technology (KTH), Sweden
16.15-16.45 Coffee and Exhibition	
SESSION 5 Structure based ligand design Chair: Lennart Bunch	
16.45-17.15	Cancer drug discovery using fragment-based methods Stephen W. Fesik, Vanderbilt University, USA

TIME MONDAY JUNE 20	
17.15-17.45	From hydrogen bonds to hydrophobicity: problems and solutions? Antti Poso, University of Eastern Finland, Finland
19.30	Conference dinner at the Grand Hotel

TIME TUESDAY JUNE 21	
SESSION 6 Protein-protein interactions Chair: Joel Barrish	
09.00-09.45	Toward drugging the undruggable James Wells, University of California at San Francisco (UCSF), USA
09.45-10.15	Targeting protein-protein interactions in the brain Kristian Strømgaard, University of Copenhagen, Denmark
10.15-10.45 Coffee and Exhibition	
SESSION 7 ADMET profiling Chair: Jan-Erik Nyström	
10.45-11.15	Toxicogenomics in discovery lead selection and investigative toxicology Bruce Car, Bristol-Myers Squibb, USA
11.15-11.45	Influencing chemical design with safety data Scott Boyer, AstraZeneca, Sweden
11.45-13.00 Lunch and Exhibition	
SESSION 8 Cancer and epigenetics Chair: Antti Poso	
13.00-13.30	Direct inhibition of bromodomain-containing proteins James Bradner, Dana-Farber Cancer Institute, Boston, USA
13.30-14.00	Targeting cancer stress signatures with DNA repair inhibitors Thomas Helleday, Stockholm University; Gray Institute for Radiation Oncology & Biology, University of Oxford
14.00-14.30	Development of chemical probes for histone demethylases Rasmus Prætorius Clausen, University of Copenhagen, Denmark
14.30-15.00 Coffee and Exhibition	
SESSION 9 Closing lectures Chair: Gerhard Ecker	
15.00-15.25	Integrative knowledge management and modelling in pharmaceutical research Ferran Sanz, IMIM, Universitat Pompeu Fabra, Barcelona, Spain
15.25-16.10	Development of dibenzosuberones as potent and extremely selective p38 MAPK inhibitors Stefan Laufer, University of Tübingen, Germany
16.10	Closing of the meeting Anders Karlén, Jeff Zablocki, Gerhard Ecker